CTOs on the Move

QUATRx Pharmaceuticals Company

www.quatrx.com

 
QUATRx Pharmaceuticals Company is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.quatrx.com
  • 777 E Eisenhower Pkwy
    Ann Arbor, MI USA 48108
  • Phone: 734.913.9900

Executives

Name Title Contact Details

Similar Companies

Dance Biopharm

Dance Biopharm is a private company focused on developing novel inhaled formulations of medicines to treat diabetes and other serious chronic diseases.

Trinity Biomedical

Trinity Biomedical is a Menomonee Falls, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Specialty Hospital Of Midwest City

Specialty Hospital Of Midwest City is a Oklahoma City, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aptevo Therapeutics

Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. We leverage the innovative ADAPTIR™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients.

Genelux

Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company`s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination with platinum-doublet + bevacizumab compared to platinum-doublet + bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux` discovery and development efforts revolves around the company`s proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.